{"product_id":"wc-0efe51bcb5f34c14-51156","title":"The Brigham Innovations and New Practices in Internal Medicine 2026","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003eOakstone The Brigham Innovations and New Practices in Internal Medicine 2026\u003c\/h1\u003e\r\n\u003ch2\u003eThe Brigham Internal Medicine 2026 | Harvard Medical School Faculty, Cardiology, Diabetes, Obesity, Infectious Diseases, Gastroenterology, Nephrology, Pulmonology, Geriatrics, AI \u0026amp; Clinical Practice Updates\u003c\/h2\u003e\r\nThe \u003cstrong\u003eOakstone The Brigham Innovations and New Practices in Internal Medicine 2026\u003c\/strong\u003e provides a comprehensive, evidence-based educational update on emerging clinical developments, new treatment strategies, diagnostic advances, and evolving practice guidelines across the major specialties of internal medicine.\r\n\r\nProduced by \u003cstrong\u003eOakstone Publishing (CMEinfo)\u003c\/strong\u003e with educational content from \u003cstrong\u003eBrigham and Women's Hospital\u003c\/strong\u003e, this program brings together expert Harvard Medical School faculty to examine important innovations affecting everyday clinical practice.\r\n\r\nOriginally released on \u003cstrong\u003eAugust 31, 2026\u003c\/strong\u003e, this educational video program addresses recent advances in cardiovascular medicine, diabetes, obesity, infectious diseases, gastroenterology, hepatology, nephrology, pulmonary medicine, rheumatology, geriatrics, neurology, women's health, preventive medicine, and primary care.\r\n\r\nThe \u003cstrong\u003eBrigham Innovations and New Practices in Internal Medicine 2026\u003c\/strong\u003e curriculum emphasizes practical application of current evidence, diagnostic reasoning, individualized treatments, and evidence-based clinical decision-making.\r\n\r\nThe program also examines rapidly developing areas of contemporary medicine, including artificial intelligence and ChatGPT, longevity science, emerging obesity medications, diabetes technology, health equity, cannabinoid medicine, opioid use disorder, HIV prevention, and new cardiovascular therapies.\r\n\r\nRather than focusing exclusively on traditional disease reviews, the program explores what has changed in internal medicine and how these developments can be incorporated into patient care.\r\n\r\nClinical presentations and case-based discussions help clinicians evaluate new evidence, understand evolving medical recommendations, and integrate contemporary treatment options into practice.\r\n\u003ch2\u003eCourse Details\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e Oakstone The Brigham Innovations and New Practices in Internal Medicine 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial Program:\u003c\/strong\u003e The Brigham Internal Medicine: Innovations and New Practices\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eContent Institution:\u003c\/strong\u003e Brigham and Women's Hospital\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAcademic Affiliation:\u003c\/strong\u003e Harvard Medical School\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePublisher:\u003c\/strong\u003e Oakstone Publishing \/ CMEinfo\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal Live Course:\u003c\/strong\u003e May 11–15, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal Video Release:\u003c\/strong\u003e August 31, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal CME Credit Expiration:\u003c\/strong\u003e August 30, 2029\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Online Video Educational Program\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePrimary Specialty:\u003c\/strong\u003e Internal Medicine\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAdditional Focus:\u003c\/strong\u003e Hospital Medicine, Primary Care, Cardiology, Endocrinology, Gastroenterology, Nephrology, Pulmonology, Neurology, Infectious Diseases, Rheumatology, Geriatrics and Women's Health\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse Directors:\u003c\/strong\u003e Ole-Petter R. Hamnvik, MB BCh BAO, MMSc, and Colleen A. Monaghan, MD\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial AMA CME:\u003c\/strong\u003e Up to 33.5 AMA PRA Category 1 Credits™\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial ABIM MOC:\u003c\/strong\u003e Up to 33.5 Points\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEducational Approach:\u003c\/strong\u003e Expert Video Lectures, Clinical Cases, Evidence-Based Reviews and Practice-Focused Updates\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe original Oakstone course provides CME and MOC credit opportunities to eligible registered participants who complete the required evaluation and post-test.\r\n\r\nPublisher credit, official course registration, and online platform access are not included with separately distributed MedicalAmboss educational files.\r\n\u003ch2\u003eTarget Audience\u003c\/h2\u003e\r\nThe program is designed for healthcare professionals seeking practical updates on contemporary internal medicine.\r\n\r\nThe target audience includes:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eInternal Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eGeneral Internists\u003c\/li\u003e\r\n \t\u003cli\u003eHospitalists\u003c\/li\u003e\r\n \t\u003cli\u003ePrimary Care Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eFamily Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eGeneral Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003eCardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eEndocrinologists\u003c\/li\u003e\r\n \t\u003cli\u003eGastroenterologists\u003c\/li\u003e\r\n \t\u003cli\u003eNephrologists\u003c\/li\u003e\r\n \t\u003cli\u003ePulmonologists\u003c\/li\u003e\r\n \t\u003cli\u003eInfectious Disease Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eGeriatricians\u003c\/li\u003e\r\n \t\u003cli\u003eRheumatologists\u003c\/li\u003e\r\n \t\u003cli\u003eNeurologists\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced Practice Providers\u003c\/li\u003e\r\n \t\u003cli\u003ePhysician Assistants\u003c\/li\u003e\r\n \t\u003cli\u003eNurse Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Residents\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eOther Healthcare Professionals Involved in Adult Medical Care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program is particularly useful for clinicians who wish to understand important changes in disease management, diagnostic testing, preventive care, and therapeutic approaches.\r\n\u003ch2\u003eProgram Overview\u003c\/h2\u003e\r\nInternal medicine continues to evolve as new clinical evidence, medical technologies, treatments, and guidelines influence healthcare delivery.\r\n\r\nPhysicians must interpret these developments while managing patients with complex medical conditions, multimorbidity, and competing treatment priorities.\r\n\r\nThe \u003cstrong\u003eBrigham Internal Medicine 2026\u003c\/strong\u003e program addresses these challenges through an extensive review of recent innovations and their practical implications.\r\n\r\nThe curriculum covers:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHeart Failure Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eAtrial Fibrillation\u003c\/li\u003e\r\n \t\u003cli\u003eValvular Heart Disease\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Risk Reduction\u003c\/li\u003e\r\n \t\u003cli\u003eLipid-Lowering Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eAnticoagulation\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension\u003c\/li\u003e\r\n \t\u003cli\u003eDiabetes Technology\u003c\/li\u003e\r\n \t\u003cli\u003eDiabetes Treatment Guidelines\u003c\/li\u003e\r\n \t\u003cli\u003eObesity Medications\u003c\/li\u003e\r\n \t\u003cli\u003eDietary Obesity Management\u003c\/li\u003e\r\n \t\u003cli\u003ePrimary Aldosteronism\u003c\/li\u003e\r\n \t\u003cli\u003eThyroid Disorders in Pregnancy\u003c\/li\u003e\r\n \t\u003cli\u003eBone Health\u003c\/li\u003e\r\n \t\u003cli\u003eMetabolic Dysfunction-Associated Steatotic Liver Disease\u003c\/li\u003e\r\n \t\u003cli\u003eGERD and Barrett's Esophagus\u003c\/li\u003e\r\n \t\u003cli\u003eHelicobacter pylori\u003c\/li\u003e\r\n \t\u003cli\u003eIrritable Bowel Syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Kidney Disease\u003c\/li\u003e\r\n \t\u003cli\u003eAntimicrobial Stewardship\u003c\/li\u003e\r\n \t\u003cli\u003eVaccinations\u003c\/li\u003e\r\n \t\u003cli\u003eSexually Transmitted Infections\u003c\/li\u003e\r\n \t\u003cli\u003eHIV Prevention\u003c\/li\u003e\r\n \t\u003cli\u003eDoxy-PEP\u003c\/li\u003e\r\n \t\u003cli\u003eAsthma\u003c\/li\u003e\r\n \t\u003cli\u003eCOPD\u003c\/li\u003e\r\n \t\u003cli\u003eHeadache Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eStroke Management\u003c\/li\u003e\r\n \t\u003cli\u003eDementia and Alzheimer's Disease\u003c\/li\u003e\r\n \t\u003cli\u003eLongevity Science\u003c\/li\u003e\r\n \t\u003cli\u003eGeriatric Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eRheumatology\u003c\/li\u003e\r\n \t\u003cli\u003eGout and Crystal Deposition Disease\u003c\/li\u003e\r\n \t\u003cli\u003eMenopause Management\u003c\/li\u003e\r\n \t\u003cli\u003eGynecologic Cancer Screening\u003c\/li\u003e\r\n \t\u003cli\u003ePelvic Floor Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eCancer Screening\u003c\/li\u003e\r\n \t\u003cli\u003eDermatology\u003c\/li\u003e\r\n \t\u003cli\u003eDepression and Anxiety\u003c\/li\u003e\r\n \t\u003cli\u003eOpioid Use Disorder\u003c\/li\u003e\r\n \t\u003cli\u003eArtificial Intelligence in Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eHealth Equity\u003c\/li\u003e\r\n \t\u003cli\u003eExercise and Preventive Medicine\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program emphasizes translating recent clinical developments into patient-centered, evidence-based practice.\r\n\u003ch2\u003eLearning Objectives\u003c\/h2\u003e\r\nAfter completing the original educational program, participants should be better able to:\r\n\u003col start=\"1\" data-spread=\"true\"\u003e\r\n \t\u003cli\u003eInterpret current evidence and emerging clinical developments relevant to internal medicine practice.\u003c\/li\u003e\r\n \t\u003cli\u003eApply current clinical guidelines and evidence-based recommendations to the evaluation and management of common and complex medical conditions.\u003c\/li\u003e\r\n \t\u003cli\u003eApply updated diagnostic and clinical reasoning strategies to evaluate challenging patient presentations.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate contemporary pharmacologic, procedural, technological, and nonpharmacologic treatments into individualized management plans.\u003c\/li\u003e\r\n \t\u003cli\u003eDeliver equitable, inclusive, and patient-centered care that considers race, ethnicity, sex, gender identity, sexual orientation, disability status, and other individual patient factors.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eComplete 2026 Course Curriculum\u003c\/h1\u003e\r\nThe following lectures and faculty are organized by clinical specialty for easier review. This organization is based on the supplied course curriculum rather than a claim that the recordings are arranged in this exact sequence.\r\n\u003ch2\u003eSession I – Cardiology and Cardiovascular Medicine\u003c\/h2\u003e\r\n\u003ch3\u003eTreatment of Heart Failure in 2026\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Anju Nohria, MD, MSc\r\n\r\nReviews contemporary developments in heart failure diagnosis and treatment.\r\n\r\nImportant clinical considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHeart Failure Classification\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure With Reduced Ejection Fraction\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure With Preserved Ejection Fraction\u003c\/li\u003e\r\n \t\u003cli\u003eGuideline-Directed Medical Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eSGLT2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eVolume Management\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eNew Treatment Strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eAtrial Fibrillation\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Paul C. Zei, MD, PhD, FHRS, FACC\r\n\r\nExamines current approaches to atrial fibrillation management.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAtrial Fibrillation Diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eRate Control\u003c\/li\u003e\r\n \t\u003cli\u003eRhythm Control\u003c\/li\u003e\r\n \t\u003cli\u003eStroke Prevention\u003c\/li\u003e\r\n \t\u003cli\u003eAnticoagulation\u003c\/li\u003e\r\n \t\u003cli\u003eCatheter Ablation\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Risk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Treatment Selection\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003ePercutaneous Approaches to Valvular Disease\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Pinak B. Shah, MD\r\n\r\nReviews advances in catheter-based treatment of valvular heart disease.\r\n\r\nRelevant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAortic Valve Disease\u003c\/li\u003e\r\n \t\u003cli\u003eMitral Valve Disease\u003c\/li\u003e\r\n \t\u003cli\u003eTranscatheter Valve Interventions\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n \t\u003cli\u003eStructural Heart Disease\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Risk\u003c\/li\u003e\r\n \t\u003cli\u003eMultidisciplinary Valve Care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eRecent Advances in Lipid Therapy and Cardiovascular Risk Reduction\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Pradeep Natarajan, MD, MMSc\r\n\r\nExamines contemporary approaches to lipid management and cardiovascular prevention.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eLDL Cholesterol Reduction\u003c\/li\u003e\r\n \t\u003cli\u003eAtherosclerotic Cardiovascular Disease\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eStatin Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eNon-Statin Lipid Treatments\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Lipid-Lowering Agents\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Prevention\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eThrombosis and Anticoagulation\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Gregory Piazza, MD, MS\r\n\r\nReviews developments in thrombotic disease and anticoagulant therapy.\r\n\r\nTopics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eVenous Thromboembolism\u003c\/li\u003e\r\n \t\u003cli\u003eDeep Vein Thrombosis\u003c\/li\u003e\r\n \t\u003cli\u003ePulmonary Embolism\u003c\/li\u003e\r\n \t\u003cli\u003eDirect Oral Anticoagulants\u003c\/li\u003e\r\n \t\u003cli\u003eBleeding Risk\u003c\/li\u003e\r\n \t\u003cli\u003eAnticoagulation Management\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Duration\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eBest Practices in Hypertension Management\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Romela Petrosyan, MD, SM, FASN, FACP\r\n\r\nExamines evidence-based approaches to hypertension.\r\n\r\nImportant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBlood Pressure Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Risk\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension Guidelines\u003c\/li\u003e\r\n \t\u003cli\u003ePharmacological Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eResistant Hypertension\u003c\/li\u003e\r\n \t\u003cli\u003eSecondary Hypertension\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Treatment Goals\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eAging and the Cardiovascular System\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Ami Bhatt, MD\r\n\r\nReviews cardiovascular changes associated with aging.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCardiovascular Aging\u003c\/li\u003e\r\n \t\u003cli\u003eVascular Function\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Structure\u003c\/li\u003e\r\n \t\u003cli\u003eAge-Related Cardiovascular Risk\u003c\/li\u003e\r\n \t\u003cli\u003eFunctional Assessment\u003c\/li\u003e\r\n \t\u003cli\u003ePreventive Strategies\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession II – Diabetes, Endocrinology and Obesity Medicine\u003c\/h2\u003e\r\n\u003ch3\u003eThyroid Disease in Pregnancy\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Athanasios Bikas, MD, PhD\r\n\r\nExamines thyroid disorders during pregnancy, including diagnostic assessment, maternal-fetal considerations, and treatment planning.\r\n\u003ch3\u003eAdvances in Diabetes Technology\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Nadine E. Palermo, DO\r\n\r\nReviews developments in continuous glucose monitoring, insulin delivery technologies, and technology-supported diabetes management.\r\n\u003ch3\u003eBone Health in 2026\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Sharon H. Chou, MD\r\n\r\nExamines osteoporosis, bone health assessment, fracture prevention, and evolving treatment strategies.\r\n\u003ch3\u003eDiabetes Management – New Drugs, Approaches, and Guidelines\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Marie E. McDonnell, MD\r\n\r\nReviews contemporary diabetes medications, treatment guidelines, cardiovascular and renal considerations, and individualized glycemic management.\r\n\u003ch3\u003eDietary Approaches to Obesity Management\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Chika V. Anekwe, MD, MPH\r\n\r\nExplores dietary interventions, nutritional planning, weight management, and evidence-based lifestyle strategies for obesity treatment.\r\n\u003ch3\u003ePrimary Aldosteronism\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Anand Vaidya, MD, MMSc\r\n\r\nReviews recognition, screening, diagnosis, and treatment considerations for primary aldosteronism as a cause of secondary hypertension.\r\n\u003ch3\u003eWhat’s New in Obesity Medications, Devices, and Procedures\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Priya Jaisinghani, MD, DABOM\r\n\r\nExamines newer pharmacologic, device-based, and procedural approaches to obesity management.\r\n\r\nTopics of clinical relevance include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAnti-Obesity Medications\u003c\/li\u003e\r\n \t\u003cli\u003eIncretin-Based Therapies\u003c\/li\u003e\r\n \t\u003cli\u003eGLP-1 Receptor Agonists\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Safety\u003c\/li\u003e\r\n \t\u003cli\u003eWeight-Loss Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eObesity Procedures\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Weight Management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession III – Gastroenterology and Hepatology\u003c\/h2\u003e\r\n\u003ch3\u003eUpdate in MASLD\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e M. Valerie Lin, MD\r\n\r\nReviews metabolic dysfunction-associated steatotic liver disease, including risk assessment, noninvasive evaluation, metabolic risk factors, and treatment considerations.\r\n\u003ch3\u003eUpdates in Upper Gastrointestinal Disorders: GERD, Barrett’s Esophagus, and H. pylori\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Molly L. Perencevich, MD\r\n\r\nExamines updated approaches to upper gastrointestinal conditions.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eGastroesophageal Reflux Disease\u003c\/li\u003e\r\n \t\u003cli\u003eBarrett's Esophagus\u003c\/li\u003e\r\n \t\u003cli\u003eHelicobacter pylori\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Testing\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Management\u003c\/li\u003e\r\n \t\u003cli\u003eSurveillance\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Selection\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eWhat’s New in Irritable Bowel Syndrome\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Kyle D. Staller, MD, MPH\r\n\r\nReviews current developments in irritable bowel syndrome diagnosis and treatment, including symptom-based evaluation, therapeutic selection, dietary considerations, and patient-centered management.\r\n\u003ch2\u003eSession IV – Infectious Diseases\u003c\/h2\u003e\r\n\u003ch3\u003eHot Topics in Infectious Diseases\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Sarah P. Hammond, MD\r\n\r\nExamines emerging infectious disease developments and clinically important updates relevant to internal medicine.\r\n\u003ch3\u003eResponsible Use of Antibiotics\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Paul E. Sax, MD\r\n\r\nReviews antimicrobial stewardship and appropriate antibiotic prescribing.\r\n\r\nTopics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAntibiotic Selection\u003c\/li\u003e\r\n \t\u003cli\u003eAntimicrobial Resistance\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Stewardship\u003c\/li\u003e\r\n \t\u003cli\u003eAvoiding Unnecessary Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Duration\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Safety\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eUpdate on Immunizations\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Daniel A. Solomon, MD, FIDSA\r\n\r\nReviews current vaccination strategies, immunization recommendations, adult preventive care, and special population considerations.\r\n\u003ch3\u003eUpdate on STIs, PrEP, and Doxy PEP\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Kevin L. Ard, MD, MPH\r\n\r\nExamines contemporary approaches to sexually transmitted infection prevention and management.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eSTI Screening\u003c\/li\u003e\r\n \t\u003cli\u003eHIV Prevention\u003c\/li\u003e\r\n \t\u003cli\u003ePre-Exposure Prophylaxis\u003c\/li\u003e\r\n \t\u003cli\u003eDoxycycline Post-Exposure Prophylaxis\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003ePreventive Counseling\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-Based Recommendations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession V – Nephrology\u003c\/h2\u003e\r\n\u003ch3\u003eWhat’s New, Innovative, and Controversial in Chronic Kidney Disease\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e J. Kevin Tucker, MD\r\n\r\nReviews emerging evidence and current clinical controversies in chronic kidney disease management.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eChronic Kidney Disease\u003c\/li\u003e\r\n \t\u003cli\u003eKidney Function Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eAlbuminuria\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Risk\u003c\/li\u003e\r\n \t\u003cli\u003eRenal-Protective Treatments\u003c\/li\u003e\r\n \t\u003cli\u003eCKD Progression\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Guidelines\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Patient Management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession VI – Geriatric Medicine, Aging and Longevity\u003c\/h2\u003e\r\n\u003ch3\u003eLongevity Overview\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Julia V. Loewenthal, MD\r\n\r\nIntroduces important concepts in longevity medicine, healthy aging, and the interpretation of emerging evidence related to aging interventions.\r\n\u003ch3\u003eLongevity Keynote – Aging and Longevity for the Internist: Why and Why Now?\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Louise Aronson, MD, MFA\r\n\r\nExplores the relevance of longevity science and aging-related healthcare to contemporary internal medicine.\r\n\u003ch3\u003eAging Biomarkers\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Lewis A. Lipsitz, MD\r\n\r\nExamines biological markers associated with aging, their potential applications, and limitations in clinical interpretation.\r\n\u003ch3\u003eLongevity Cases\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eJulia V. Loewenthal, MD\u003c\/li\u003e\r\n \t\u003cli\u003eJay R. Luthar, MD, DipABLM\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nUses clinical cases to examine practical considerations in longevity medicine and healthy aging.\r\n\u003ch3\u003eUpdate in Geriatrics – The Latest Studies and Their Clinical Relevance\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Suzanne E. Salamon, MD\r\n\r\nReviews important recent geriatric medicine research and its implications for the care of older adults.\r\n\u003ch3\u003eUpdate in Dementia and Alzheimer's Disease\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Gad A. Marshall, MD\r\n\r\nExamines developments in dementia diagnosis, cognitive assessment, Alzheimer's disease, disease-modifying treatments, and patient management.\r\n\u003ch2\u003eSession VII – Rheumatology\u003c\/h2\u003e\r\n\u003ch3\u003eUpdate in Rheumatology\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Eli M. Miloslavsky, MD\r\n\r\nReviews important developments in inflammatory and autoimmune rheumatological disorders.\r\n\r\nTopics may inform clinical evaluation, diagnosis, treatment selection, and ongoing disease monitoring.\r\n\u003ch3\u003eAdvances in Gout and Crystal Deposition Disease\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Sara K. Tedeschi, MD, MPH\r\n\r\nExamines recent developments in gout and related crystal deposition diseases.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eGout\u003c\/li\u003e\r\n \t\u003cli\u003eHyperuricemia\u003c\/li\u003e\r\n \t\u003cli\u003eCrystal Arthritis\u003c\/li\u003e\r\n \t\u003cli\u003eUrate-Lowering Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Flare Management\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Disease Control\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession VIII – Pulmonary Medicine\u003c\/h2\u003e\r\n\u003ch3\u003eAsthma Update\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Elliot Israel, MD, MSc (Hon)\r\n\r\nReviews developments in asthma diagnosis, treatment selection, inhaled therapies, biologic treatment considerations, and individualized disease management.\r\n\u003ch3\u003eUpdate in COPD\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Craig P. Hersh, MD, MPH\r\n\r\nExamines contemporary chronic obstructive pulmonary disease management.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCOPD Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eExacerbation Risk\u003c\/li\u003e\r\n \t\u003cli\u003eBronchodilator Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eInhaled Treatments\u003c\/li\u003e\r\n \t\u003cli\u003ePreventive Care\u003c\/li\u003e\r\n \t\u003cli\u003eSmoking Cessation\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession IX – Neurology\u003c\/h2\u003e\r\n\u003ch3\u003eAdvances in Diagnosis and Management of Headache\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Carolyn A. Bernstein, MD, FAHS\r\n\r\nReviews advances in headache assessment and treatment, including migraine evaluation, preventive therapies, and individualized treatment strategies.\r\n\u003ch3\u003eStroke Management in 2026\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Alexis T. Roy, MD, MSc\r\n\r\nExamines contemporary approaches to stroke assessment, treatment, secondary prevention, and multidisciplinary management.\r\n\u003ch2\u003eSession X – Women's Health\u003c\/h2\u003e\r\n\u003ch3\u003ePelvic Floor Disorders – Medical Management and More\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Neeraj Kohli, MD, MBA\r\n\r\nReviews pelvic floor dysfunction, urinary symptoms, clinical evaluation, conservative management, and treatment considerations.\r\n\u003ch3\u003eGynecologic Cancer Screening\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Colleen M. Feltmate, MD\r\n\r\nExamines current screening approaches, cancer risk assessment, preventive strategies, and appropriate referral considerations.\r\n\u003ch3\u003eUpdate in Menopause Management\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Deborah Gomez Kwolek, MD, FACP, MSCP, FAMWA\r\n\r\nReviews clinical developments in menopause management.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMenopausal Symptoms\u003c\/li\u003e\r\n \t\u003cli\u003eHormonal Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eNon-Hormonal Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Safety\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Women's Health\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Clinical Decisions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession XI – Primary Care and General Internal Medicine\u003c\/h2\u003e\r\n\u003ch3\u003eClinical Cases in Dermatology\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Adam D. Lipworth, MD\r\n\r\nReviews common and challenging dermatological presentations through clinical cases, emphasizing recognition, differential diagnosis, and appropriate management.\r\n\u003ch3\u003eCancer Screening Cases\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Leigh H. Simmons, MD\r\n\r\nExamines practical cancer screening decisions using case-based examples.\r\n\r\nImportant considerations include screening eligibility, risk assessment, preventive counseling, and interpretation of recommendations.\r\n\u003ch3\u003eDepression and Anxiety\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e David S. Kroll, MD\r\n\r\nReviews assessment and treatment of depression and anxiety in medical practice.\r\n\r\nTopics include diagnostic evaluation, pharmacological therapy, nonpharmacological approaches, and longitudinal care.\r\n\u003ch3\u003eBest Practices for Preoperative Evaluation\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Adam C. Schaffer, MD, MPH\r\n\r\nExamines evidence-based preoperative assessment and optimization.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePerioperative Risk\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eMedication Management\u003c\/li\u003e\r\n \t\u003cli\u003eComorbid Conditions\u003c\/li\u003e\r\n \t\u003cli\u003eSurgical Preparation\u003c\/li\u003e\r\n \t\u003cli\u003eAppropriate Testing\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eExercise for Health – What’s New in 2026\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Meagan M. Wasfy, MD, MPH\r\n\r\nReviews the role of physical activity in health promotion, cardiovascular prevention, chronic disease management, and personalized exercise recommendations.\r\n\u003ch2\u003eSession XII – Emerging and Innovative Areas of Medicine\u003c\/h2\u003e\r\n\u003ch3\u003eInnovations in Cannabinoid Medicine\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Jordan Tishler, MD\r\n\r\nExamines contemporary evidence, clinical controversies, potential therapeutic applications, and safety considerations involving cannabinoid medicine.\r\n\u003ch3\u003eAdvancing Patient Equity in Medicine\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Bram P. Wispelwey, MD, MS, MPH\r\n\r\nReviews approaches to improving equity in healthcare.\r\n\r\nImportant themes include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHealthcare Disparities\u003c\/li\u003e\r\n \t\u003cli\u003eAccess to Care\u003c\/li\u003e\r\n \t\u003cli\u003eInclusive Clinical Practice\u003c\/li\u003e\r\n \t\u003cli\u003eSocial Determinants of Health\u003c\/li\u003e\r\n \t\u003cli\u003ePatient-Centered Care\u003c\/li\u003e\r\n \t\u003cli\u003eQuality Improvement\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eAI and ChatGPT\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Rebecca G. Mishuris, MD, MS, MPH, FAMIA\r\n\r\nExplores the use of artificial intelligence and generative AI in clinical medicine.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eClinical Decision Support\u003c\/li\u003e\r\n \t\u003cli\u003eGenerative Artificial Intelligence\u003c\/li\u003e\r\n \t\u003cli\u003eDocumentation\u003c\/li\u003e\r\n \t\u003cli\u003eHealthcare Workflows\u003c\/li\u003e\r\n \t\u003cli\u003eAI Reliability\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Safety\u003c\/li\u003e\r\n \t\u003cli\u003eBias\u003c\/li\u003e\r\n \t\u003cli\u003eHuman Oversight\u003c\/li\u003e\r\n \t\u003cli\u003eAppropriate Clinical Applications\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eManagement of Opioid Use Disorder\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Joji Suzuki, MD\r\n\r\nReviews evidence-based approaches to opioid use disorder, including clinical assessment, medication treatment, harm reduction, relapse prevention, and coordinated care.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eMajor Topics Covered\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eThe Brigham Internal Medicine 2026\u003c\/li\u003e\r\n \t\u003cli\u003eInnovations and New Practices in Internal Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eHarvard Medical School Faculty\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-Based Internal Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Practice Updates\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure\u003c\/li\u003e\r\n \t\u003cli\u003eAtrial Fibrillation\u003c\/li\u003e\r\n \t\u003cli\u003eValvular Heart Disease\u003c\/li\u003e\r\n \t\u003cli\u003eLipid Management\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Risk Reduction\u003c\/li\u003e\r\n \t\u003cli\u003eThrombosis\u003c\/li\u003e\r\n \t\u003cli\u003eAnticoagulation\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension\u003c\/li\u003e\r\n \t\u003cli\u003eDiabetes Technology\u003c\/li\u003e\r\n \t\u003cli\u003eContinuous Glucose Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eDiabetes Management\u003c\/li\u003e\r\n \t\u003cli\u003eObesity Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eAnti-Obesity Medications\u003c\/li\u003e\r\n \t\u003cli\u003eThyroid Disease in Pregnancy\u003c\/li\u003e\r\n \t\u003cli\u003eOsteoporosis\u003c\/li\u003e\r\n \t\u003cli\u003eBone Health\u003c\/li\u003e\r\n \t\u003cli\u003ePrimary Aldosteronism\u003c\/li\u003e\r\n \t\u003cli\u003eMASLD\u003c\/li\u003e\r\n \t\u003cli\u003eGERD\u003c\/li\u003e\r\n \t\u003cli\u003eBarrett's Esophagus\u003c\/li\u003e\r\n \t\u003cli\u003eHelicobacter pylori\u003c\/li\u003e\r\n \t\u003cli\u003eIrritable Bowel Syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Kidney Disease\u003c\/li\u003e\r\n \t\u003cli\u003eInfectious Diseases\u003c\/li\u003e\r\n \t\u003cli\u003eAntibiotic Stewardship\u003c\/li\u003e\r\n \t\u003cli\u003eImmunizations\u003c\/li\u003e\r\n \t\u003cli\u003eHIV PrEP\u003c\/li\u003e\r\n \t\u003cli\u003eDoxy-PEP\u003c\/li\u003e\r\n \t\u003cli\u003eGeriatric Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eLongevity\u003c\/li\u003e\r\n \t\u003cli\u003eAging Biomarkers\u003c\/li\u003e\r\n \t\u003cli\u003eAlzheimer's Disease\u003c\/li\u003e\r\n \t\u003cli\u003eDementia\u003c\/li\u003e\r\n \t\u003cli\u003eRheumatology\u003c\/li\u003e\r\n \t\u003cli\u003eGout\u003c\/li\u003e\r\n \t\u003cli\u003eCrystal Deposition Disease\u003c\/li\u003e\r\n \t\u003cli\u003eAsthma\u003c\/li\u003e\r\n \t\u003cli\u003eCOPD\u003c\/li\u003e\r\n \t\u003cli\u003eHeadache Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eStroke\u003c\/li\u003e\r\n \t\u003cli\u003ePelvic Floor Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eMenopause\u003c\/li\u003e\r\n \t\u003cli\u003eCancer Screening\u003c\/li\u003e\r\n \t\u003cli\u003eDermatology\u003c\/li\u003e\r\n \t\u003cli\u003eDepression and Anxiety\u003c\/li\u003e\r\n \t\u003cli\u003ePreoperative Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eExercise Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eCannabinoid Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eHealth Equity\u003c\/li\u003e\r\n \t\u003cli\u003eArtificial Intelligence\u003c\/li\u003e\r\n \t\u003cli\u003eChatGPT in Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eOpioid Use Disorder\u003c\/li\u003e\r\n \t\u003cli\u003ePatient-Centered Care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eCardiovascular Medicine and Risk Reduction\u003c\/h2\u003e\r\nCardiovascular disease remains a major area of clinical decision-making in internal medicine.\r\n\r\nThe program examines treatment developments involving heart failure, atrial fibrillation, hypertension, thrombosis, lipid abnormalities, and valvular heart disease.\r\n\r\nThese educational sessions support clinical understanding of evolving evidence and the appropriate selection of patient-specific cardiovascular treatments.\r\n\u003ch2\u003eDiabetes, Obesity and Metabolic Medicine\u003c\/h2\u003e\r\nAdvances in diabetes technology and obesity management continue to influence treatment approaches across internal medicine.\r\n\r\nThe course reviews newer pharmacological therapies, diabetes technologies, nutritional strategies, and other interventions relevant to metabolic disease.\r\n\r\nThe curriculum also addresses primary aldosteronism, thyroid disease during pregnancy, osteoporosis, and metabolic liver disease.\r\n\u003ch2\u003eGastroenterology, Hepatology and Kidney Disease\u003c\/h2\u003e\r\nCommon gastrointestinal, hepatic, and renal disorders frequently require long-term medical management.\r\n\r\nThe program includes updates involving MASLD, GERD, Barrett's esophagus, H. pylori infection, irritable bowel syndrome, and chronic kidney disease.\r\n\r\nThe educational focus emphasizes diagnostic reasoning, current evidence, risk assessment, and individualized treatment decisions.\r\n\u003ch2\u003eInfectious Diseases and Preventive Medicine\u003c\/h2\u003e\r\nThe infectious disease curriculum addresses important clinical developments affecting outpatient and hospital medicine.\r\n\r\nMajor topics include antimicrobial stewardship, vaccination, STI prevention, HIV PrEP, Doxy-PEP, and emerging infectious disease issues.\r\n\r\nThese sessions are relevant to clinicians responsible for antimicrobial prescribing, preventive counseling, and infection management.\r\n\u003ch2\u003eHealthy Aging, Longevity and Dementia\u003c\/h2\u003e\r\nAging and longevity are major educational themes of the 2026 program.\r\n\r\nThe curriculum examines:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHealthy Aging\u003c\/li\u003e\r\n \t\u003cli\u003eLongevity Science\u003c\/li\u003e\r\n \t\u003cli\u003eAging Biomarkers\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Aging\u003c\/li\u003e\r\n \t\u003cli\u003eGeriatric Research\u003c\/li\u003e\r\n \t\u003cli\u003eAlzheimer's Disease\u003c\/li\u003e\r\n \t\u003cli\u003eDementia Management\u003c\/li\u003e\r\n \t\u003cli\u003eOlder Adult Care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe presentations help clinicians evaluate emerging longevity research and its practical implications for patients.\r\n\u003ch2\u003eClinical Reasoning and Evidence-Based Care\u003c\/h2\u003e\r\nAn important theme throughout the program is translating scientific advances into daily medical practice.\r\n\r\nClinicians are encouraged to integrate:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCurrent Research\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Guidelines\u003c\/li\u003e\r\n \t\u003cli\u003eIndividual Patient Characteristics\u003c\/li\u003e\r\n \t\u003cli\u003ePharmacologic Therapies\u003c\/li\u003e\r\n \t\u003cli\u003eProcedural Treatments\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Technologies\u003c\/li\u003e\r\n \t\u003cli\u003eNonpharmacologic Interventions\u003c\/li\u003e\r\n \t\u003cli\u003eShared Decision-Making\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe course emphasizes applying clinical evidence while recognizing uncertainty and the need for individualized care.\r\n\u003ch2\u003eArtificial Intelligence and Emerging Clinical Technologies\u003c\/h2\u003e\r\nArtificial intelligence is an increasingly prominent area of healthcare innovation.\r\n\r\nThe curriculum includes a dedicated presentation addressing AI and ChatGPT.\r\n\r\nRelevant considerations include potential benefits for clinical workflows, decision support, documentation, education, and information management, alongside the need for accuracy, safety, privacy, and clinician oversight.\r\n\u003ch2\u003eCourse Leadership\u003c\/h2\u003e\r\n\u003ch3\u003eOle-Petter R. Hamnvik, MB BCh BAO, MMSc\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAssociate Professor of Medicine, Harvard Medical School\u003c\/li\u003e\r\n \t\u003cli\u003eProgram Director, Endocrinology Fellowship, Brigham and Women's Hospital\u003c\/li\u003e\r\n \t\u003cli\u003eEducation Editor, NEJM Group\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eColleen A. Monaghan, MD\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAssistant Professor of Medicine and Pediatrics, Harvard Medical School\u003c\/li\u003e\r\n \t\u003cli\u003eAssociate Medical Director, Brigham and Women's Primary Care\u003c\/li\u003e\r\n \t\u003cli\u003eAssociate Program Director, Harvard Medicine-Pediatrics Residency\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe course features expert teaching faculty from Harvard Medical School and affiliated medical institutions.\r\n\u003ch2\u003eContinuing Medical Education\u003c\/h2\u003e\r\nThe original Oakstone educational activity provides up to:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\u003cstrong\u003e33.5 AMA PRA Category 1 Credits™\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003e33.5 ABIM Maintenance of Certification Points\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eOriginal Release Date:\u003c\/strong\u003e August 31, 2026\r\n\r\n\u003cstrong\u003eCredit Expiration Date:\u003c\/strong\u003e August 30, 2029\r\n\r\nThe original educational provider requires eligible participants to complete the relevant evaluation and post-test requirements to claim credits.\r\n\u003ch3\u003eImportant CME Notice\u003c\/h3\u003e\r\nPurchasing separately distributed educational files through MedicalAmboss does not itself provide:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eOfficial Oakstone CME Credits\u003c\/li\u003e\r\n \t\u003cli\u003eABIM MOC Points\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Certificates\u003c\/li\u003e\r\n \t\u003cli\u003eOakstone Course Registration\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher Subscription Access\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Online Platform Access\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher Accounts\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher-Hosted Benefits\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nCredit availability and official course participation are governed by Oakstone's requirements.\r\n\u003ch2\u003eWhy This Course Is Relevant\u003c\/h2\u003e\r\nThe \u003cstrong\u003eOakstone The Brigham Innovations and New Practices in Internal Medicine 2026\u003c\/strong\u003e program provides a broad review of developments affecting contemporary internal medicine.\r\n\r\nIts combination of cardiovascular medicine, metabolic disease, pulmonary medicine, infectious diseases, nephrology, gastroenterology, geriatrics, neurology, women's health, psychiatry, and preventive medicine makes it particularly relevant to practicing internists.\r\n\r\nThe inclusion of artificial intelligence, longevity, newer obesity treatments, diabetes technology, evolving cardiovascular therapies, and contemporary preventive medicine expands the curriculum beyond conventional internal medicine reviews.\r\n\r\nThe program supports professional education by connecting emerging evidence with practical clinical reasoning, individualized treatment strategies, and patient-centered medical care.\r\n\u003ch2\u003eOfficial Program Reference and MedicalAmboss Purchase Scope\u003c\/h2\u003e\r\n\u003cstrong\u003eOfficial Oakstone Course:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/oakstone.com\/the-brigham-internal-medicine-innovations-and-new-practices\/\" data-rich-text-autolink=\"\"\u003ehttps:\/\/oakstone.com\/the-brigham-internal-medicine-innovations-and-new-practices\/\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eOriginal Brigham 2026 Course Syllabus:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/www.innovationsintmed2026.com\/\" data-rich-text-autolink=\"\"\u003ehttps:\/\/www.innovationsintmed2026.com\/\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eMedicalAmboss Product:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/medicalamboss.com\/product\/oakstone-the-brigham-innovations-and-new-practices-in-internal-medicine-2026\/\" data-rich-text-autolink=\"\"\u003ehttps:\/\/medicalamboss.com\/product\/oakstone-the-brigham-innovations-and-new-practices-in-internal-medicine-2026\/\u003c\/a\u003e\r\n\r\nThe official references describe the original educational program, its learning objectives, faculty, release date, and accreditation.\r\n\r\nThe original program information does not establish the exact inventory of files included with a separately distributed MedicalAmboss product.\r\n\r\n\u003cstrong\u003eMedicalAmboss File Scope:\u003c\/strong\u003e This listing describes the educational subject matter for reference. Provider registration, live attendance, streaming-platform access, CME or other credit, certificates, memberships, apps, accounts, and publisher-hosted extras are not included unless explicitly listed as store files.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eShort Description\u003c\/h2\u003e\r\n\u0026lt;div style=\"border:2px solid #1677b8;border-radius:10px;padding:12px;background:#f7fbfe;\"\u0026gt;\r\n\r\n\u003cstrong\u003eOakstone The Brigham Innovations and New Practices in Internal Medicine 2026\u003c\/strong\u003e provides a comprehensive Harvard-affiliated internal medicine update covering emerging treatments, clinical guidelines, diagnostic advances, and evidence-based patient management.\r\n\r\nOriginally released August 31, 2026, this Oakstone educational video program includes expert presentations addressing cardiology, diabetes, obesity, infectious diseases, gastroenterology, nephrology, pulmonary medicine, geriatrics, rheumatology, neurology, women's health, clinical reasoning, and artificial intelligence.\r\n\r\n\u003csection class=\"medicalamboss-related-resources\"\u003e\u003c\/section\u003e","brand":"Amboss","offers":[{"title":"Default Title","offer_id":67982438105242,"sku":"MED-AMB10552","price":16.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/macs-0efe51bcb5-51156-51170-05025991f33609dc4a8c.jpg?v=1793146690","url":"https:\/\/ambosscourse.com\/products\/wc-0efe51bcb5f34c14-51156","provider":"Amboss","version":"1.0","type":"link"}